Blasting Off Neuroblastoma: Updates to Management of Neuroblastoma

New Orleans, LA US
October 14, 2021

This activity will provide pharmacists, residents, and pharmacy technicians with information in order to help determine how to provide safe and efficacious therapy options for the patients with high risk or refractory/relapsed neuroblastoma. The Children’s Oncology Group (COG) trials have been studying and using dinutuximab as antibody therapy for treatment of high risk and refractory/relapsed neuroblastoma. Recently, trials have demonstrated that adding on antibody therapy to standard treatment can help with prognosis and survival of neuroblastoma, which has lead to the discovery of dinutuximab. However, this is a costly intravenous therapy which requires long administration infusions and requires inpatient admissions. With the recently FDA approved agent naxitamab with indications for high risk and refractory/relapsed neuroblastoma, and newer primary literature emerging, naxitamab has the potential to be more cost effective and allow outpatient administration of the infusion for much shorter times. This presentation will review primary literature behind the use of antibody therapy, and especially for naxitamab, for high risk and relapsed/refractory neuroblastoma and help identify its place in practice.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Describe the classifications of neuroblastoma and its related prognoses
  2. Discuss the different stages of treatment for high risk neuroblastoma
  3. Evaluate the literature on the updated management of high risk, relapsed, or refractory neuroblastoma

Pharmacy technician learning objectives

  1. Recognize brand and generic names of antibody therapy agents used in high risk, relapsed and/or refractory neuroblastoma
  2. Recall the special preparation instructions for naxitamab
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Course opens: 
Course expires: 
Event starts: 
10/14/2021 - 12:00pm CDT
Event ends: 
10/14/2021 - 1:00pm CDT
Ochsner Medical Center
1514 Jefferson Hwy.
New Orleans, LA 70121
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose.
The presenter will discuss off-label use of drugs.
Planning committee members
Kathryn Cook, PharmD, BCPPS
Pediatric Hematology/Oncology Clinical Pharmacy Specialist
Ochsner Medical Center
Bailey Wise, PharmD, BCPS
Solid Organ Transplant Clinical Pharmacy Specialist
Ochsner Medical Center
Course reviewer
Gretchen Brummel, PharmD, BCPS
Consulting Director, Pharmacy
Vizient, Inc.
Malgorzata Labedz, PharmD
PGY2 Oncology Pharmacy Resident
Ochsner Medical Center
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-21-188-L01-P
Universal Activity Number: JA0006103-9999-21-188-L01-T

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Please login or register to take this course.